Esperion Therapeutics (ESPR) Research Hub

Esperion Therapeutics (ESPR) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-07-14, shares last closed at 3.18 USD (-0.31%), in a uptrend — price above rising 50-DMA, 50-DMA above 200-DMA. Valuation: trailing P/E -131.40, market cap 0.66B. This hub links to the full technical, earnings and options research available for ESPR.

Last updated 2026-07-14 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, US
Last close3.18 USD (-0.31%)
52-week range1.13 USD – 4.18 USD
Trend regimeUptrend
14-day RSI58.3 (Bullish)
Trailing P/E-131.40
Market cap0.66B
Dividend yield99.37%

Available research for ESPR

Earnings

ESPR earnings: real EPS beat/miss history, analyst consensus Hold, P/E -131.40. Updated 2026-07-23.

Options: Covered Call

Covered Call on ESPR: how it works, illustrative setup around the real 3.18 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on ESPR: how it works, illustrative setup around the real 3.18 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on ESPR: how it works, illustrative setup around the real 3.18 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

ESPR technical analysis: uptrend, last 3.18 USD, RSI 58.3, 52w range 1.13 USD–4.18 USD, real support/resistance. Updated 2026-07-14.

Frequently asked questions

What sector is ESPR in?

Esperion Therapeutics (ESPR) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.

Is ESPR in an uptrend or downtrend?

As of 2026-07-14, ESPR is in a uptrend — price above rising 50-DMA, 50-DMA above 200-DMA. See the full technical research page for support and resistance levels.

What is ESPR's trailing P/E ratio?

ESPR's trailing P/E is -131.40, with a market cap of 0.66B. See the earnings research page for full valuation detail.